In the field of gastric cancer, attention is paid to whether the first immuno-oncology drug insurance benefit registration can be achieved. As a result of the coverage, it is possible to propose the HIRA in April for Opdivo, an immune anticancer drug with PD-1 inhibitory mechanism, from Ono Korea Pharmaceuticals and Korea BMS Pharmaceuticals. In June 2021, Opdivo added an indication for 'combination therapy with fluoropyrimidine-based and platinum-based chemotherapy as the first-line treatment for advanced or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma' in Korea. It is the first and only approved immune anti-cancer drug in Korea for first-line gastric cance